


The Involvement of Interstitial Palladin Expression in Patients with Chronic Kidney Disease

Naoki Yamamoto, Norihiko Sakai, Yuta Yamamura, Kyoaki Ito,
Ichiro Mizushima, Akinori Hara, Miho Shimizu, Takashi Wada, Yasunori Iwata

Department of Nephrology and Rheumatology, Kanazawa University

Actin polymerization drives fibroblast activation via MRTF-SRF signaling



LPA : lysophosphatidic acid

TGF- β_1 : Transforming growth factor- β

MRTF : myocardin-related transcription factor


SRF : serum response factor

Sakai N, et al. FASEB J 2013



Sakai N, et al. Kidney Int 2017

Yamamura Y, Sakai N, et al. FASEB J 2023

Molecular pathway that regulates actin cytoskeleton was significantly correlated with eGFR and COL1A1 expression




<Enrichment analysis>



Actin-associated proteins


- Vinculin
- Palladin
- Actinin- α 1
- Profilin 1
- Cofilin 1
- Zyxin
- VASP

Serum creatinine level, BUN level, hydroxyproline, ECM expression were suppressed in fibroblast-specific palladin deficient mice




α SMA expression was suppressed in palladin^{iFBKO}


α SMA / GAPDH mRNA





α SMA / GAPDH protein




Legend:
Palladin^{WT} (white box)
Palladin^{iFBKO} (grey box)
N=5~7
* p < 0.05



α SMA staining




α SMA positive area



$\times 200$
Bars: 100 μ m

Palladin promotes kidney fibrosis through ECM deposition and myofibroblast differentiation



Hypothesis

Interstitial palladin is involved in kidney dysfunction and fibrosis in patients with chronic kidney disease

Palladin expression is highly enriched in fibroblasts of the human kidney

Method


- Public database (GSE 109564 and GSE 114156)
Human healthy adult kidney and rejecting kidney allograft biopsy




↓ Using R version 4.5.2

<Single cell analysis >

- Clustering analysis
- Expression analysis



CD, collecting duct; EC, endothelial cell;
LOH (AL), loop of Henle, ascending limb;
LOH (DL), loop of Henle, distal limb;
Mono, monocyte; PT, proximal tubule



Methods

<Participants>

Japanese patients who underwent kidney biopsy for CKD at Kanazawa University Hospital between March 2022 and December 2023

CKD was defined by either persistent urinary abnormalities or eGFR < 60 mL/min/1.73m² for at least three months.

<Exclusion criteria>

- Patients with acute kidney injury
- Insufficient tissue
- Patients who did not provide consent

<Outcome measures>

- Immunofluorescence (palladin, α SMA)
- Azan-Mallory (AZAN) staining (fibrotic area)
- eGFR, UPCR at the time of biopsy
- Urinary β 2MG and NAG

α SMA: α -smooth muscle actin

eGFR: estimated glomerular filtration ratio

<Study design>

- Cross-sectional study


Baseline clinical characteristics of patients included in the study

	Number of patients	57
Age (years)		56.4 ± 17.1
Men, n(%)		26(45.6)
Primary disease n(%)		
IgA nephropathy		11(19.3)
Tubulointerstitial nephritis		10(17.5)
Benign nephrosclerosis		6(10.5)
ANCA-associated vasculitis		5(8.8)
Diabetic kidney disease		5(8.8)
Lupus nephritis		4(7.0)
Membranous nephropathy		4(7.0)
Minimal change disease		3(5.3)
Focal segmental glomerulosclerosis		2(3.5)
Thrombotic microangiopathy		2(3.5)
Others		5(8.8)
eGFR (mL/min/1.73 m ²)		49.0 ± 23.78
UPCR (g/gCr)		2.6 ± 3.2
β ₂ MG (μg/L)		2851 ± 4763
NAG (IU/L)		13.4 ± 12.3



UPCR, urine protein-creatinine ratio

Palladin was colocalized with α SMA-expressing cells in kidney interstitium


Immunohistochemistry
(DAB staining)




Immunofluorescence



DAPI








Merged



Bars, 100 μ m

Interstitial palladin-positive area was positively correlated with fibrotic area and inversely correlated with eGFR



Interstitial palladin-positive area was independently associated with fibrotic area and eGFR after adjustment for age, sex, and UPCR

Multiple regression analysis

Fibrotic area model

eGFR model

Variable	β (SE)	p value	Variable	β (SE)	p value
Palladin-positive area (per 1% increase)	1.4 (0.4)	<0.001	Palladin-positive area (per 1% increase)	-2.8 (0.7)	<0.001
Age (per 1-year increase)	0.1 (0.1)	0.10	Age (per 1-year increase)	-0.8 (0.1)	<0.001
Men (vs women)	0.2 (1.9)	0.91	Men (vs women)	-6.7 (4.0)	0.10
UPCR (per 1 g/gCr increase)	0.2 (0.3)	0.54	UPCR (per 1 g/gCr increase)	1.0 (0.6)	0.10

SE, standard error

Conclusion

Interstitial palladin is associated with kidney dysfunction and fibrosis in patients with CKD

